title: Incremental and infrequent hemodialysis: a new paradigm for both dialysis initiation and conservative management.
abstract: Registry or national dialysis data show that a sizeable proportion of contemporary dialysis patients have substantial levels of residual kidney function especially upon transitioning to dialysis therapy. However, among incident hemodialysis patients, the prevailing paradigm has been to initiate "full-dose" triweekly treatment schedules irrespective of native kidney function in most developed countries. Recognizing the benefits of residual kidney function upon the health and survival of dialysis patients, there has been growing interest in incremental hemodialysis, in which dialysis frequency and dose are tailored according to the degree of patients' residual kidney function. Infrequent hemodialysis can also be used for those who prefer a more conservative approach in managing uremia. Clinical practice guidelines support the use of twice-weekly hemodialysis among patients with adequate residual kidney function (renal urea clearance >3 mL/min/1.73 m2), and a growing body of evidence indicates that incremental hemodialysis is associated with better preservation of residual kidney function without adversely impacting survival. Nonetheless, incremental hemodialysis remains an underutilized approach in this population. In this review, we will discuss the history of the twice- versus triweekly hemodialysis schedules; current clinical practice guidelines regarding infrequent hemodialysis; emerging data on incremental treatment regimens and outcomes; and guidelines for the practical implementation of incremental and infrequent hemodialysis in the clinical setting.
authors.affiliation: Division of Nephrology and Hypertension, University of California Irvine School of Medicine, Orange, CA, USA - crhee1@uci.edu.
authors.forename: Connie M
authors.initials: CM
authors.lastname: Rhee
authors.affiliation: Division of Nephrology and Hypertension, University of California Irvine School of Medicine, Orange, CA, USA.
authors.forename: Mehrdad
authors.initials: M
authors.lastname: Ghahremani-Ghajar
authors.affiliation: Division of Nephrology and Hypertension, University of California Irvine School of Medicine, Orange, CA, USA.
authors.forename: Yoshitsugu
authors.initials: Y
authors.lastname: Obi
authors.affiliation: Division of Nephrology and Hypertension, University of California Irvine School of Medicine, Orange, CA, USA.
authors.forename: Kamyar
authors.initials: K
authors.lastname: Kalantar-Zadeh
mesh_terms: D000818:Animals; D000072700:Conservative Treatment; D003404:Creatinine / Q000652:urine; D006801:Humans; D007668:Kidney / Q000502:physiology; D007676:Kidney Failure, Chronic / Q000401:mortality / Q000628:therapy*; D010641:Phenotype; D011788:Quality of Life; D006435:Renal Dialysis / Q000379:methods*; D013997:Time Factors; D016896:Treatment Outcome; D014508:Urea / Q000097:blood
chemical_list: D014508:Urea; D003404:Creatinine